586 related articles for article (PubMed ID: 10080600)
21. Allogeneic stem cell transplantation for patients with chronic myeloid leukemia: risk stratified approach with a long-term follow-up.
Zuckerman T; Katz T; Haddad N; Fineman R; Dann EJ; Avivi I; Ofran Y; Gavish I; Faibish T; Sahar D; Hertz E; Sabo E; Reisner Y; Rowe JM
Am J Hematol; 2012 Sep; 87(9):875-9. PubMed ID: 22847303
[TBL] [Abstract][Full Text] [Related]
22. Prognostic factors for long-term survival in leukemic marrow recipients with special emphasis on age and prophylaxis for graft-versus-host disease.
Aschan J; Ringdén O
Clin Transplant; 1994 Jun; 8(3 Pt 1):258-70. PubMed ID: 8061365
[TBL] [Abstract][Full Text] [Related]
23. Immunological effects of donor lymphocyte infusion in patients with chronic myelogenous leukemia relapsing after bone marrow transplantation.
Castro FA; Palma PV; Morais FR; Voltarelli JC
Braz J Med Biol Res; 2004 Feb; 37(2):201-6. PubMed ID: 14762574
[TBL] [Abstract][Full Text] [Related]
24. Cytomegalovirus seropositivity adversely influences outcome after T-depleted unrelated donor transplant in patients with chronic myeloid leukaemia: the case for tailored graft-versus-host disease prophylaxis.
Craddock C; Szydlo RM; Dazzi F; Olavarria E; Cwynarski K; Yong A; Brookes P; de la Fuente J; Kanfer E; Apperley JF; Goldman JM
Br J Haematol; 2001 Jan; 112(1):228-36. PubMed ID: 11167809
[TBL] [Abstract][Full Text] [Related]
25. Allogeneic cell therapy for relapsed leukemia after bone marrow transplantation with donor peripheral blood lymphocytes.
Slavin S; Naparstek E; Nagler A; Ackerstein A; Kapelushnik J; Or R
Exp Hematol; 1995 Dec; 23(14):1553-62. PubMed ID: 8542946
[TBL] [Abstract][Full Text] [Related]
26. Bone marrow transplantation depleted of T cells followed by repletion with incremental doses of donor lymphocytes for relapsing patients with chronic myeloid leukemia: a therapeutic strategy.
Novitzky N; Rubinstein R; Hallett JM; du Toit CE; Thomas VL
Transplantation; 2000 Apr; 69(7):1358-63. PubMed ID: 10798754
[TBL] [Abstract][Full Text] [Related]
27. Survival in first or second remission after lymphocyte-depleted transplantation for Philadelphia chromosome-positive CML in first chronic phase.
Schattenberg A; Preijers F; Mensink E; Bär B; Schaap N; Geurts van Kessel A; van der Maazen R; de Witte T
Bone Marrow Transplant; 1997 Jun; 19(12):1205-12. PubMed ID: 9208114
[TBL] [Abstract][Full Text] [Related]
28. CD8+ T-cell-depleted, matched unrelated donor, allogeneic bone marrow transplantation for advanced AML using busulfan-based preparative regimens.
Kalaycio M; Rybicki L; Pohlman B; Sobecks R; Ball E; Cook D; Andresen S; Kuczkowski E; Bolwell B
Bone Marrow Transplant; 2005 Feb; 35(3):247-52. PubMed ID: 15580282
[TBL] [Abstract][Full Text] [Related]
29. The impact of partial T cell depletion on overall transplant-related toxicity, graft function and survival after HLA-identical allogeneic bone marrow transplantation in standard risk adult patients with leukemia.
Schots R; Van Riet I; Ben Othman T; Trullemans F; De Waele M; Van Camp B
Bone Marrow Transplant; 2001 Nov; 28(10):917-22. PubMed ID: 11753544
[TBL] [Abstract][Full Text] [Related]
30. Analysis of risk factors for the development of GVHD after T cell-depleted allogeneic BMT: effect of HLA disparity, ABO incompatibility, and method of T-cell depletion.
Keever-Taylor CA; Bredeson C; Loberiza FR; Casper JT; Lawton C; Rizzo D; Burns WH; Margolis DA; Vesole DH; Horowitz M; Zhang MJ; Juckett M; Drobyski WR
Biol Blood Marrow Transplant; 2001; 7(11):620-30. PubMed ID: 11760150
[TBL] [Abstract][Full Text] [Related]
31. Donor leukocyte infusions for chronic myeloid leukemia relapsed after allogeneic bone marrow transplantation.
Bär BM; Schattenberg A; Mensink EJ; Geurts Van Kessel A; Smetsers TF; Knops GH; Linders EH; De Witte T
J Clin Oncol; 1993 Mar; 11(3):513-9. PubMed ID: 8445426
[TBL] [Abstract][Full Text] [Related]
32. Donor leukocyte infusion for Japanese patients with relapsed leukemia after allogeneic bone marrow transplantation: lower incidence of acute graft-versus-host disease and improved outcome.
Shiobara S; Nakao S; Ueda M; Yamazaki H; Takahashi S; Asano S; Yabe H; Kato S; Imoto S; Maruta A; Yoshida T; Gondo H; Morishima Y; Kodera Y
Bone Marrow Transplant; 2000 Oct; 26(7):769-74. PubMed ID: 11042659
[TBL] [Abstract][Full Text] [Related]
33. Comparable outcome with T-cell-depleted unrelated-donor versus related-donor allogeneic bone marrow transplantation.
Alyea EP; Weller E; Fisher DC; Freedman AS; Gribben JG; Lee S; Schlossman RL; Stone RM; Friedberg J; DeAngelo D; Liney D; Windawi S; Ng A; Mauch P; Antin JH; Soiffer RJ
Biol Blood Marrow Transplant; 2002; 8(11):601-7. PubMed ID: 12463479
[TBL] [Abstract][Full Text] [Related]
34. Persistent donor chimaerism is consistent with disease-free survival following BMT for chronic myeloid leukaemia.
Gardiner N; Lawler M; O'Riordan J; DeArce M; Humphries P; McCann SR
Bone Marrow Transplant; 1997 Aug; 20(3):235-41. PubMed ID: 9257892
[TBL] [Abstract][Full Text] [Related]
35. Characterization of T cell repertoire in patients with graft-versus-leukemia after donor lymphocyte infusion.
Claret EJ; Alyea EP; Orsini E; Pickett CC; Collins H; Wang Y; Neuberg D; Soiffer RJ; Ritz J
J Clin Invest; 1997 Aug; 100(4):855-66. PubMed ID: 9259585
[TBL] [Abstract][Full Text] [Related]
36. [CD25 monoclonal antibody for GVHD prophylaxis in non-T-cell depleted haploidentical bone marrow transplantation for treatment of childhood leukemia].
Chen HR; Ji SQ; Yan HM; Wang HX; Liu J; Xue M; Zhu L
Zhonghua Er Ke Za Zhi; 2004 Apr; 42(4):294-8. PubMed ID: 15157394
[TBL] [Abstract][Full Text] [Related]
37. Case report of spontaneous remission of cytogenetic relapse of chronic myelogenous leukemia suggestive of progression to blast crisis after allogeneic bone marrow transplantation.
Agaliotis DP; Papenhausen PR; Moscinski LC; Elfenbein GJ
Ann Hematol; 1995 Jan; 70(1):37-41. PubMed ID: 7827205
[TBL] [Abstract][Full Text] [Related]
38. CD6+ donor marrow T-cell depletion as the sole form of graft-versus-host disease prophylaxis in patients undergoing allogeneic bone marrow transplant from unrelated donors.
Soiffer RJ; Weller E; Alyea EP; Mauch P; Webb IL; Fisher DC; Freedman AS; Schlossman RL; Gribben J; Lee S; Anderson KC; Marcus K; Stone RM; Antin JH; Ritz J
J Clin Oncol; 2001 Feb; 19(4):1152-9. PubMed ID: 11181681
[TBL] [Abstract][Full Text] [Related]
39. CD6-depleted allogeneic bone marrow transplantation for acute leukemia in first complete remission.
Soiffer RJ; Fairclough D; Robertson M; Alyea E; Anderson K; Freedman A; Bartlett-Pandite L; Fisher D; Schlossman RL; Stone R; Murray C; Freeman A; Marcus K; Mauch P; Nadler L; Ritz J
Blood; 1997 Apr; 89(8):3039-47. PubMed ID: 9108425
[TBL] [Abstract][Full Text] [Related]
40. Infusion of CD4+ donor lymphocytes induces the expansion of CD8+ donor T cells with cytolytic activity directed against recipient hematopoietic cells.
Zorn E; Wang KS; Hochberg EP; Canning C; Alyea EP; Soiffer RJ; Ritz J
Clin Cancer Res; 2002 Jul; 8(7):2052-60. PubMed ID: 12114403
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]